Завершено
Фаза III
Беларусь
КАБАЗИТАКСЕЛ (XRP6258) · Sanofi-Aventis Recherche & Developpement
Randomized, Open Label, Multi-Center Study Comparing Cabazitaxel at 25 mg/m^2 and at 20 mg/m^2 in Combination With Prednisone Every 3 Weeks to Docetaxel in Combination With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer Not Pretreated With Chemotherapy